Cytek Biosciences (CTKB) Competitors $4.15 +0.14 (+3.49%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.14 -0.01 (-0.12%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTKB vs. TXG, EYPT, TRNS, ALNT, AEHR, LAB, SENS, FEIM, MASS, and QSIShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. Cytek Biosciences vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Transcat Allient Aehr Test Systems Standard BioTools Senseonics Frequency Electronics 908 Devices Quantum-Si 10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment. Which has more volatility & risk, TXG or CTKB? 10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Which has preferable earnings and valuation, TXG or CTKB? Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.91-$182.63M-$0.70-20.43Cytek Biosciences$200.45M2.63-$6.02M-$0.05-83.00 Does the media favor TXG or CTKB? In the previous week, 10x Genomics had 9 more articles in the media than Cytek Biosciences. MarketBeat recorded 11 mentions for 10x Genomics and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.97 beat 10x Genomics' score of 0.84 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TXG or CTKB more profitable? Cytek Biosciences has a net margin of -3.27% compared to 10x Genomics' net margin of -13.13%. Cytek Biosciences' return on equity of -1.66% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Cytek Biosciences -3.27%-1.66%-1.30% Do institutionals and insiders have more ownership in TXG or CTKB? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Comparatively, 10.3% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend TXG or CTKB? 10x Genomics presently has a consensus target price of $13.54, indicating a potential downside of 5.30%. Cytek Biosciences has a consensus target price of $5.60, indicating a potential upside of 34.94%. Given Cytek Biosciences' higher probable upside, analysts plainly believe Cytek Biosciences is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38Cytek Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Summary10x Genomics and Cytek Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$527.98M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E Ratio-83.0021.0031.3026.05Price / Sales2.63357.30455.25117.77Price / Cash119.5944.5038.0259.36Price / Book1.408.129.536.60Net Income-$6.02M-$54.72M$3.26B$265.65M7 Day Performance3.49%2.62%2.14%2.01%1 Month Performance23.15%2.68%2.81%-0.33%1 Year Performance-26.55%10.93%30.70%19.04% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences3.5062 of 5 stars$4.15+3.5%$5.60+34.9%-20.7%$527.98M$200.45M-83.00500TXG10x Genomics3.7305 of 5 stars$13.46+0.7%$13.54+0.6%-35.7%$1.66B$610.78M-19.231,240News CoverageEYPTEyepoint Pharmaceuticals1.8819 of 5 stars$11.33+2.2%$25.38+124.0%+31.4%$764.41M$43.27M-4.23120Positive NewsTRNSTranscat2.5078 of 5 stars$82.24+0.9%$112.20+36.4%-25.7%$759.88M$288.14M57.511,245Analyst ForecastAnalyst RevisionALNTAllient2.8407 of 5 stars$44.56+2.4%$35.00-21.5%+126.8%$737.53M$529.97M51.812,525News CoverageAnalyst RevisionAEHRAehr Test Systems1.8557 of 5 stars$19.39+5.9%N/A+34.5%$547.74M$58.97M-149.1490Options VolumeLABStandard BioTools2.5149 of 5 stars$1.27+3.3%$1.55+22.0%-34.9%$467.18M$174.43M-3.97620Positive NewsSENSSenseonics2.2991 of 5 stars$0.47-0.7%$1.55+230.1%+15.4%$382.49M$25.47M-3.6190News CoveragePositive NewsFEIMFrequency Electronics1.1618 of 5 stars$28.38-7.8%N/A+106.3%$299.33M$69.81M11.49200News CoverageMASS908 Devices2.6773 of 5 stars$6.27-5.4%$8.00+27.6%+59.7%$237.76M$59.63M-11.6160Analyst UpgradeQSIQuantum-Si2.4081 of 5 stars$1.09-0.9%$3.48+218.8%+21.4%$222.74M$3.06M-1.60150 Related Companies and Tools Related Companies 10x Genomics Alternatives Eyepoint Pharmaceuticals Alternatives Transcat Alternatives Allient Alternatives Aehr Test Systems Alternatives Standard BioTools Alternatives Senseonics Alternatives Frequency Electronics Alternatives 908 Devices Alternatives Quantum-Si Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTKB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access